Articles tagged "Cytomeglovirus"

2018 American Transplant Congress
Significant Anti-CMV/BKV Effect of a Modern Everolimus-Based Regimen Comparted to a Standard Tacrolimus-MPA Regimen in De Novo Kidney Transplant Recipients: ATHENA 12 Months Data on Infections
A. Hauser,¹ C. Sommerer,¹ B. Suwelack,¹ D. Dragun,¹ O. Witzke,¹ C. Hugo,¹ N. Kamar,² P. Merville,² P. Schenker,¹ M. Junge,³ F. Thaiss,¹ B. Nashan.¹
¹Athena Study Group, Germany; ²Athena Study Group, France; ³Novartis, Pharma, Germany.
The ATHENA trial was designed to compare everolimus [EVR] in combination with tacrolimus [TAC] or cyclosporine A [CyA] vs. a standard regimen of mycophenolic acid…
2018 American Transplant Congress
Cause of ESRD is Not Associated with Risk of Post-Transplant CMV Infection
S. Panzer, S. Peery, B. Astor, A. Djamali, T. Singh.
University of Wisconsin Madison, Madison, WI.
Purpose: Cytomegalovirus (CMV) infection is commonly encountered following kidney transplantation and is associated with patient morbidity and mortality. While preventative pharmacotherapy is used to prevent…
2018 American Transplant Congress
Evaluation of a Change in CMV Prevention Strategy Following Pediatric SOT
S. Pangonis, A. Miethke, F. Flores, M. Schecter, S. Kocoshis, D. Lazear, T. Hemmelgam, B. Taylor, G. Paulsen, L. Danziger-Isakov.
Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Optimal cytomegalovirus(CMV) prevention strategy following solid organ transplantation(SOT) is uncertain. We report on CMV disease with implementation of prophylaxis-based prevention with intensive monitoring.We retrospectively evaluated…
2018 American Transplant Congress
CMV-Specific Cell-Mediated Immunity after Valgancyclovir Prophylaxis Predicts Late Onset CMV Infection in Kidney Transplant Patients
M. Jarque,¹ E. Crespo,¹ E. Melilli,² A. Manonelles,² N. Montero,² S. Luque,¹ J. Cruzado,^1,2 J. Grinyo,^1,2 O. Bestard.^1,2
¹Experimental Nephrology Laboratory, IDIBELL, Barcelona, Spain; ²Nephrology Department, Bellvitge University Hospital, Barcelona, Spain.
Background: There is currently no means to predict late-onset CMV infection after a long course of post-transplant Valgancyclovir prophylaxis therapy and its development still negatively…
2018 American Transplant Congress
Relation between Seroprevalence of Cytomegalovirus and Graft Survival in Japanese Kidney Transplant Recipients: The Japan Academic Consortium of Kidney Transplantation Study
K. Miyake,^1,2 M. Okumi,¹ K. Unagami,³ Y. Kakuta,¹ H. Shirakawa,⁴ K. Omoto,⁵ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Kidney Transplantation, Shonan Kamakura General Hospital, Kamakura, Japan; ³Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ⁴Urology, Okubo Hospital, Tokyo, Japan; ⁵Urology, Toda Chuo General Hospital, Saitama, Japan.
BackgroundCytomegalovirus (CMV) infection is one of major causes of morbidity in kidney transplant recipients (KTRs). However, the current prevalence of CMV in KTRs and the…
2018 American Transplant Congress
Efficacy of Two Valganciclovir Dosing Strategies in Intermediate and High-Risk Liver Transplant Recipients
K. Belfield,¹ M. Malinis,² E. Cohen.¹
¹Department of Pharmacy, Yale New Haven Hospital, New Haven, CT; ²Section of Infectious Diseases, Yale School of Medicine, New Haven, CT.
Purpose: There is interest in reduced dosing and duration of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant (LT) recipients to minimize side effects…
2018 American Transplant Congress
Kidney Transplant Allocation with CMV Seromatching Reduces CMV Infection without Affecting Wait Times
A. Narra,¹ L. Strasfeld,² D. Basuli,¹ M. Stack,¹ E. Langewisch,³ A. Olyaei,¹ D. Norman,^1,4 J. Lockridge.^1,4
¹Transplant Nephrology, Oregon Health and Science University, Portland, OR; ²Infectious Diseases, OHSU, Portland, OR; ³Transplant Nephrology, University of Nebraska Medical Center, Omaha, NE; ⁴Transplant Nephrology, Portland VA, Portland, OR.
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in kidney transplant recipients.A pre-transplant allocation strategy by matching deceased kidney donors and recipients…
2018 American Transplant Congress
Clinical Validation of a Novel ELISpot-Based In Vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients
B. Banas,¹ D. Steubl,² L. Renders,² D. Chittka,¹ M. Banas,¹ T. Wekerle,³ M. Koch,⁴ O. Witzke,⁵ A. Muehlfeld,⁶ C. Sommerer,⁷ A. Habicht,⁸ C. Hugo,⁹ T. Huenig,¹⁰ M. Lindemann,⁵ T. Schmidt,¹¹ A. Rascle,¹¹ S. Barabas,¹¹ L. Deml,¹¹ R. Wagner,^1,11 B. Kraemer,¹² B. Krueger.¹²
¹University Clinic, Regensburg, Germany; ²Clinic rechts der Isar TUM, Munich, Germany; ³Medical University, Vienna, Austria; ⁴University Clinic, Hamburg-Eppendorf, Germany; ⁵University Hospital, Essen, Germany; ⁶Uniklinik RWTH, Aachen, Germany; ⁷University Hospital, Heidelberg, Germany; ⁸LMU Medical Center, Munich, Germany; ⁹University Hospital, Dresden, Germany; ¹⁰University Hospital, Wuerzburg, Germany; ¹¹Lophius Biosciences, Regensburg, Germany; ¹²UMM Uni. Heidelberg, Mannheim, Germany.
Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause ofCMV reactivation and associated complications in solid-organ transplantation. Reliably assessing CMV-CMI is desirable to individually…
2018 American Transplant Congress
A National Survey of Valganciclovir Dosing Strategies in Pediatric Solid Organ Transplant Recipients
S. Shaikh, N. Panek, J. Park.
MedStar Georgetown University Hospital, Washington DC; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago; Michigan Medicine, Ann Arbor.
Objective: The FDA-approved pediatric indication of valganciclovir (VGCV) is limited to cytomegalovirus (CMV) prophylaxis in heart and kidney transplants. The recommended regimen is a daily…
2018 American Transplant Congress
The Incidence of Polyomavirus-BK and Cytomegalovirus Infections in Renal Transplant Recipients Following Rituximab Administration
A. Kraljevic, C. D'Agostino, C. Kane, K. Cunningham, A. Shetty, C. Richardson.
Northwestern Memorial Hospital, Chicago, IL.
Rituximab is an antibody that binds to the CD20 antigen on B cells resulting in rapid and prolonged depletion. At Northwestern Memorial Hospital, a single…